



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

December 3, 2020

Laura Shawver  
Chief Executive Officer  
Silverback Therapeutics, Inc.  
500 Fairview Ave N, Suite 600  
Seattle, WA 98109

**Re: Silverback Therapeutics, Inc.  
Registration Statement on Form S-1  
Exhibit Nos. 10.10, 10.11, 10.12  
Filed November 10, 2020  
File No. 333-250009**

Dear Dr. Shawver:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance